Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1953 - Frequency of driver mutations in EGFR wt NSCLC using mass spectrometry: Experience of Area Vasta Romagna


08 Oct 2016


Poster Display


Elisa Chiadini


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


E. Chiadini1, L. Capelli1, A. Delmonte2, N. De Luigi2, C. Dazzi3, C. Casanova3, A. Gamboni4, M. Papi5, M.M. Tumedei1, S. Bravaccini1, A. Dubini6, M. Puccetti7, L. Crinò8, P. Ulivi1

Author affiliations

  • 1 Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 - Meldola/IT
  • 2 Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 - Meldola/IT
  • 3 Medical Oncology, Ospedale Civile di Ravenna - S.ta Maria delle Croci, 48121 - Ravenna/IT
  • 4 Medical Oncology, Ospedale degli Infermi, 48018 - Faenza/IT
  • 5 Medical Oncology, Ospedale Infermi, 47923 - Rimini/IT
  • 6 Pathology Unit, Ospedale Pierantoni, 47121 - Forlì/IT
  • 7 Pathology Unit, Ospedale Civile di Ravenna - S.ta Maria delle Croci, 48121 - Ravenna/IT
  • 8 Medical Oncology, Ospedale S. Maria della Misericordia, 06156 - Perugia/IT


Abstract 1953


Targeted therapy of advanced non-small-cell lung cancer (NSCLC) has changed the outcome of patients with specific gene alterations. In particular, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors have improved the outcome of patients with EGFR-mutated lung adenocarcinoma (ADC). We analyzed the frequency of other potentially targetable driver alterations in a series of advanced EGFR-wild type (wt) NSCLC patients.


461 advanced EGFR-wt NSCLC patients enrolled from Area Vasta Romagna between January 2013 to December 2014 were included in the study. KRAS, BRAF, ERBB2, PIK3CA, NRAS, ALK, MAP2K1, RET and DDR2 mutations were analyzed by Myriapod®Lung Status kit (Diatech Pharmacogenetics) on Maldi-TOF Mass Spectrometry (MassARRAY® AGENA BIOSCIENCE). ERBB4 was evaluated by direct sequencing and EML4-ALK and ROS1 rearrangements were assessed by immunohistochemistry or fluorescence in situ hybridization.


217 (47%) patients showed at least one alteration. In particular, 71%, 6.5%, 2.7%, 1.8%, 1.4% and 1.4% patients had mutations in KRAS, BRAF, PIK3CA, NRAS, ERBB2 and MAP2K1 genes, respectively. Only one (0.5%) patient showed a mutation in ERBB4 gene. EML4-ALK and ROS1 rearrangements were observed in 10.6% and 4.1% patients, respectively. The clinical characteristics of mutated patients are reported in Table 1. Overlapping mutations were observed in 5 (2.3%) KRAS-mutated patients: one (20%) was mutated in PIK3CA, 3 (60%) showed an EML4-ALK translocation and one (20%) had a ROS1 rearrangement. One (0.5%) patient showed both BRAF and PIK3CA alterations. Correlation analyses between the different mutations and patient outcome are ongoing. Table.

Gene No. of mutated patients Age Gender Smoking Habits


Driver mutations were detected in about 50% of EGFR-wt lung ADC patients. Such alterations could represent potential targets for therapy and could be evaluated in routine multiplexed testing to obtain a wider tumor molecular characterization.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.